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ABSTRACT
The Edwards SAPIENTM transcatheter heart valve
(Edwards Lifesciences LLC, Irvine, CA, USA) is
approved by the US Food and drug administration
for use in the aortic position in patients with
severe aortic stenosis who are not surgical
candidates. This approval was backed by data
from the Placement of AoRTic TraNscathetER
Valve (PARTNER) I clinical trial, which showed
the valve to be superior to standard medical
therapy in high-risk nonoperative patients in
cohort B of the trial. Although insertion of the
valve is considered to be very safe, stroke, major
vascular complications, and conduction
abnormalities are the most frequent procedural
complications. A dedicated team of physicians
trained in structural cardiac interventions,
including two interventional cardiologists, an
echocardiographer, and a cardiac surgeon, are
involved in every case. Improvements in valve
design and streamlining of the delivery system, as
well as favorable long-term outcomes, will
hopefully pave the way for wider patient use in
the future.
Keywords: Aortic stenosis; Cardiology;
Edwards SAPIEN valve; Interventional
cardiology; Stents; Transcatheter aortic valve
replacement
INTRODUCTION
The concept of transcatheter insertion of heart
valves as a treatment option for valvular heart
disease has been around since the 1960s [1]. In
the 1990s, transcatheter implantation of aortic
valves in pig models was described [2], but it
was not until 2000 that Bonhoeffer et al. [3]
described the first implantation of a
transcatheter pulmonic valve in a human
being. The valve was comprised of a fresh
bovine jugular vein, containing a native
biological valve that was attached to a
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platinum stent. It was implanted in a 12-year-
old boy with pulmonic stenosis and a
degenerated right ventricle (RV) to pulmonary
artery (PA) conduit with RV dysfunction. 2 years
following this report, Cribier et al. [4] described
the first percutaneous transcatheter
implantation of an aortic valve prosthesis in a
57-year-old patient with calcific aortic stenosis.
This valve consisted of three equine pericardial
leaflets mounted within a tubular, slotted,
stainless steel balloon-expandable stent,
designed to achieve a diameter of 21–22 mm.
This aortic valve model was the predecessor of
the Edwards SAPIENTM transcatheter heart valve
(THV) (Edwards Lifesciences). Over the next
decade, the field of transcatheter valve
replacement skyrocketed with multiple large-
scale randomized trials, which ultimately lead
to the Edwards SAPIEN THV being the first
percutaneous valve approved by the US food
and drug administration (FDA) for inoperable
patients with calcific aortic valve stenosis [5]. In
this paper, the authors review the history and
specifications of the valve, procedural steps for
transfemoral insertion of the valve, and detailed
results of the Placement of AoRTic
TraNscathetER Valve (PARTNER) I trial.
Calcific Aortic Stenosis
Calcific aortic stenosis is a common disease
process that is estimated to affect 8–12% of
patients over the age of 75 years [6]. It is a
progressive disease, and once symptoms
develop, deterioration can be quite rapid with
a high-level of morbidity and mortality. In
symptomatic patients, if left untreated, the
2-year mortality approaches 50% [7, 8].
Fortunately, in the right patient, surgical
aortic valve replacement (AVR) is an excellent
option, which leads to symptom resolution and
improved mortality [9, 10]. In patients with
little or no comorbid conditions, surgery is
quite safe and is associated with low operative
mortality [11]. However, for a large proportion
of patients with severe aortic stenosis (30%),
due to multiple comorbid conditions, surgery is
not an option [12, 13].
TRANSCATHETER AVR
Transcatheter AVR (TAVR) was first introduced
by Cribier et al. [4] in 2002 with the aim of
offering an alternative treatment option for
patients with severe symptomatic aortic
stenosis who were at high-risk for surgical AVR
[14]. Over the last 10 years since its conception,
the technique and the devices available have
rapidly evolved [15, 16]. Currently, over 50,000
patients have undergone TAVR worldwide [17],
with at least 25,000 of those performed using
the Edwards SAPIEN THV.
The Edwards SAPIEN THV
The Edwards SAPIEN THV is made up of three
equal-sized bovine pericardial leaflets that are
hand-sewn to a stainless steel, balloon-
expandable stent (Fig. 1a1, a2). A polyethylene
terephthalate (PET) fabric cuff covers the lower
portion of the stent to enable a seal with the
calcified valve, hoping to prevent paravalvular
leak. The leaflet material has been designed to
reduce leaflet stress and maximize coaptation.
The pericardial tissue is processed with the
ThermaFix Process (Edwards Lifesciences LLC)
anticalcification treatment that is utilized in the
Carpentier-Edwards PERIMOUNT MagnaTM
(Edwards Lifesciences LLC) surgical valve. The
Edwards SAPIEN THV is available in a diameter
of 23 mm (for use in native valves with an
annulus between 18 mm and 22 mm), 26 mm
(for use in native valves with an annulus
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between 21 mm and 25 mm), and outside the
US a 29 mm valve is available (for use in native
valves with an annulus between 25 mm and
27 mm). The height of these valves varies
between 14 mm and 19 mm. The 23 mm valve
requires a 22 French (Fr.) sheath for delivery and
the 26 mm valve requires a 24 Fr. sheath. The
valve is manually compressed over the delivery
balloon using a crimping tool to symmetrically
reduce the valve diameter so it can be placed
through the introducer sheath (Fig. 2).
The Edwards SAPIEN THV was approved by
the FDA in November 2011 for use in patients
with severe symptomatic calcific aortic stenosis
who are not surgical candidates [5].
The main competitor of the Edwards SAPIEN
THV is the CoreValve (Medtronic, Inc.,
Minneapolis, MN, USA). It consists of a self-
expandable nitinol stent with porcine
pericardial leaflets. The CoreValve is widely
used internationally but is still undergoing
clinical trials in the US and results are
expected to be published in 2013. Table 1
outlines the main differences between the
Edwards SAPIEN THV and the CoreValve [17].
There are multiple other valves that are
under investigation domestically and
internationally with the hope that clinical
trials will start in the US and internationally in
the near future.
In the US, the delivery system that is
currently available for the Edwards SAPIEN
THV through the transfemoral approach is the
RetroFlex 3TM Transfemoral System (Edwards
Lifesciences LLC; Fig. 1b, c). It has a distal cone
tip, which helps in advancing the THV across
tortuous vessels, reducing friction at the level of
the aortic arch, and crossing the native calcified
Fig. 1 The Edwards SAPIEN transcatheter heart valve and
RetroFlex 3 transfemoral system. The valve (a1 and a2) is
available in 23 mm or 26 mm diameter. It consists of three
equal-sized bovine pericardial cusps mounted into a
stainless-steel balloon expandable stent. The RetroFlex 3
delivery system has a tapered steerable tip (b), which
facilitates valve crossing (white arrow indicates the location
of the valve on the catheter). The handle of the RetroFlex 3
catheter (c) has a knob (white arrow) to steer the tip of the
catheter during aortic arch crossing
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Fig. 2 The Edwards SAPIEN transcatheter heart valve
being crimped on the balloon using a crimping tool.
a Stent/valve on delivery balloon. The blue/green suture
line on the valve (arrow) should be pointing towards the
yellow tip for delivery in the aortic position. b The valve
being crimped using the crimping tool (arrow). c Valve
(arrow) crimped on the delivery balloon, and covered with
the introducer/loader (d) to prevent damage to the valve
when advancing it through the sheath
Table 1 Comparison of the Edwards SAPIEN THV to the Medtronic CoreValve
Valve characteristics Edwards SAPIEN Medtronic CoreValve
Stent material Stainless steel Nitinol
Leaﬂet material Bovine pericardial Porcine pericardial
Method of expansion Balloon expandable Self-expanding
Reposition/retrievable No Yes
Available diameters, mm 23, 26a 26, 29
Treatable diameter, mm 18–25 20–27
Sheath external diameter, mm 8.4 7.0
Pacemaker requirement, % 3–8 14–40
THV transcatheter heart valve
a The Edwards SAPIEN XT valve is available in a smaller delivery diameter (7 mm) and in 29 mm size in Europe or as part
of the Placement of AoRTic TraNscathetER Valve (PARTNER) II protocol
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valve. The handle of the delivery system
includes a rotating wheel for articulation of
the flex catheter.
The newer model of the Edwards SAPIEN
THV, the Edwards SAPIEN XT THV (Edwards
Lifesciences LLC; Fig. 3a1, a2), is mounted on a
cobalt-chromium alloy frame and has several
advantages over its predecessors. Perhaps most
importantly, it has a lower profile (16 Fr. for the
23 mm valve and 19 Fr. for the 26 mm valve),
allowing for implantation in patients with
smaller vessels and reducing the risk of
vascular injury. This valve along with its
newer delivery system, the NovaFlex?TM
transfemoral system (Edwards Lifesciences
LLC; Fig. 3b, c), is widely used internationally
but is currently only available in the US through
the PARTNER II clinical trial.
Patient Selection
Careful patient selection is critically important
to ensure a successful procedure. The authors
typically use the inclusion and exclusion
criteria for the PARTNER I trial, as described in
the clinical data section of this paper. As the
Edwards SAPIEN THV is only approved for
patients who are not surgical candidates, the
Fig. 3 The Edwards SAPIEN XT transcatheter heart valve
and NovaFlex ? transfemoral system. The valve (a1 and
a2) is available in 23 mm or 26 mm in the US, and 29 mm
internationally. It consists of three bovine pericardial cusps
mounted into a cobalt-chromium balloon expandable stent.
b The NovaFlex delivery system has a much smaller tapered
yellow tip (white arrow), which facilitates crossing the aortic
valve; the black indicates valve position on the catheter
when crimped. c1 The handle of the NovaFlex has a large
front knob 1 to steer the tip of the catheter. The catheter is
advanced inside the sheath where the tip of the catheter is
at the crimped valve over the shaft. Once the catheter is in
the thoracic/abdominal aorta the locking button 2 is
pushed and the balloon catheter is retracted so that the
valve straddles the markers on the balloon. Once it is close,
then ﬁne adjustments can be made using the back knob 3
until the valve is between the two markers on the balloon.
c2 Prior to balloon inﬂation, one should push the button
(arrow) and pull the catheter back off the balloon until it is
completely away from the balloon
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authors make sure that each patient is thoroughly
evaluated by a team of physicians, including
a cardiac surgeon, an interventionalist, and
a general cardiologist, prior to receiving a
commercial TAVR. Two of the most important
factors in deciding TAVR eligibility are the
femoral vessel diameters and the aortic valve
annulus by echocardiography or computed
tomography (CT) angiography. Prior to TAVR,
each patient has their femoral/iliac vessels
evaluated by two methods: conventional
angiography and CT angiography of the chest,
thorax, abdomen, and pelvis. The minimal vessel
diameter required for sheath insertion in the
transfemoral approach is 7 mm for the 22 Fr.
sheath and 8 mm for the 24 Fr. sheath in the
absence of calcification. Vessel tortuosity should
not be considered a contraindication for the
transfemoral approach as long as the arteries
straighten out during the insertion of a stiff
guidewire. Patients with small, heavily calcified
arteries should undergo placement of the valve
through a transapical approach or via a surgical
conduit (proximal to the narrowest diameter of
the vessel or calcification) in order to prevent
vascular complications. The aortic annulus
diameter is measured by gated CT angiogram,
and by transthoracic echocardiogram and
transesophageal echocardiogram (TEE) during
the procedure. Most interventionalists rely on
TEE to choose the appropriately sized valve.
Currently, in the US, patients with an annulus




The authors prefer to perform the procedures in
the hybrid catheterization laboratory using
monoplane fluoroscopy under general
endotracheal anesthesia. However, it is also
possible to perform TAVR under deep sedation
if endotracheal intubation is contraindicated,
such as in cases of severe end-stage lung disease.
Given how sick these patients are, it is
recommended that hemodynamic monitoring
is performed throughout the procedure,
including a dedicated arterial line for blood
pressure monitoring and a triple lumen central
venous catheter. The team performing the
procedure consists of two interventional
cardiologists, one cardiothoracic surgeon, and
an echocardiographer. In addition, because of
the potential risk of complications requiring
emergent surgery, the patient’s chest is prepped
in a surgical sterile-fashion (from supra sternal
notch to the knees), and the authors have a
surgical team of nurses and technicians, and
cardiopulmonary bypass available in the room
in case of emergency. Once the patient is
intubated, the authors obtain an accurate
aortic valve annulus measurement (Fig. 4a) to
confirm that the annulus is appropriate for the
available valves. In one instance, the authors
encountered a patient where the TEE
measurement in the lab was 27 mm, which
was not appropriate for the largest available
valve, 26 mm, and the procedure was
abandoned.
Arterial Access
Because of the large caliber of the arterial
sheaths, vascular access and closure are the
most critical steps of the entire TAVR procedure.
The femoral artery is the preferred site of
insertion, and is the approved delivery method
for the Edwards SAPIEN THV. Although a
surgical cut-down was initially required to
insert the large arterial sheaths, most centers
are now performing percutaneous access. The
device has also been inserted through various
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other routes, including through a transapical
approach (as part of the PARTNER I trial),
transaxillary, and an open surgical
retroperitoneal approach in patients whose
femoral vessels are too small to accommodate
the large arterial sheath. Failure to obtain
proper arterial access can lead to major
bleeding complications. The authors always
use a fluoroscopic-guided technique for arterial
access. The authors first obtain arterial (6 Fr.)
and venous (7 Fr.) access on the contralateral
side. Once adequate arterial access is obtained
on the contralateral side, abdominal
aortography [at the bifurcation of the aorta to
the common iliacs (Fig. 5a)] is performed in
order to evaluate the location of the common
femoral bifurcation. The authors then use
fluoroscopic guidance to obtain arterial access
on the side through which the authors plan to
insert the valve. The authors typically start with
an 8 Fr. sheath, and ‘‘preclose’’ the vessel with
two Perclose ProGlideTM 6F Suture-Medicated
Closure System (Abbot Laboratories, Abbott
Park, IL, USA), one at the 10 o’clock position
and the other one at 2 o’clock position, that
remain in place during the procedure and are
used to achieve hemostasis at the end of the
case. The authors reasoning for choosing the
Perclose ProGlide instead of the Prostar XL
Percutaneous Vascular Surgical System (Abbott
Vascular, Santa Clara, CA, USA) is the cost
difference between these two devices and the
ease of use.
Angiography
An aortic root angiogram is performed in order
to have a reference view of the aortic valve and
annulus (Fig. 5b). This is usually done in slight
left anterior oblique (LAO) (10) with cranial
angulation (10). It is critical to profile the
aortic annular plane perpendicular to the screen
with the three aortic cusps in a straight line.
This line is used as a landmark for proper valve
placement. On occasions, the calcification
landmarks do not necessarily indicate the level
of annulus. Careful attention must be paid to
the location of the coronary ostia in relation to
the calcium in the valve as there have been
reports of coronary occlusion following valve
delivery [18, 19].
Crossing the Valve
After the angiogram has been completed, the
next step is to cross the valve. The authors use
an AL-1 or AL-2 catheter with a straight soft tip
Terumo Glidewire. (Terumo Medical
Fig. 4 Transesophageal views of the Edwards SAPIEN
transcatheter heart valve being deployed. a Annulus mea-
surement from leaﬂet insertion points. b Valve on delivery
balloon across the valve in a 50:50 ratio (50% ventricular to
50% aortic). c Valve leaﬂets following deployment by
transesophageal echocardiography. d Evidence of mild
paravalvular leak by transesophageal echocardiography
Cardiol Ther (2012) 1:6 Page 7 of 17
123
Corporation, Elkton, MD, USA) The authors
have found this combination to work in most
cases. The authors often create side holes in the
AL catheter so that the authors can record
pressure using this catheter. Once the catheter
is inside the left ventricle (LV), simultaneous
pressure recordings from the LV and ascending
aorta are obtained to obtain the gradient across
the valve.
The next step is to place a 5 Fr. pacing
catheter to the RV apex and to test the pacing
thresholds/rate. The authors usually choose a
rate of 160–180 beats/min and observe the
effect on blood pressure. The authors aim to
have the mean aortic pressure drop to about
50 mmHg. Pacing is a crucial step and has to be
perfected otherwise the untoward complication
of valve migration may occur. The authors
usually have one interventionalist in charge of
deciding when to pace and when to terminate
pacing. The pacing duration should be as brief
as possible, but should be terminated upon
complete balloon deflation. Some patients with
poor LV function may not tolerate rapid pacing
for a long period. Rapid RV pacing was first
described with balloon aortic valvuloplasty
(BAV) in 2001 [20] and has been an integral
part of the TAVR procedure [21].
At this point, prior to BAV, the entire team
takes a ‘‘timeout’’ to review all the necessary
steps/equipment availability in the room in case
of an emergency. A nurse who is in charge of
the patient calls the timeout and goes over a few
points (balloon size to be used, valve size to be
Fig. 5 Step-wise angiographic images of the Edwards
SAPIEN transcatheter heart valve being deployed.
a Abdominal aortogram with arrows pointing to the
external iliac vessels. b Aortic root angiogram in left
anterior oblique 10/cranial 10 projection, demonstrating
all three aortic cusps (white arrows). c Balloon aortic
valvuloplasty prior to valve insertion. d Valve being
positioned across the aortic annulus (arrow) in a 50:50
ratio (50% aortic to 50% ventricular). e Valve being
deployed. f Valve in good position following deployment
(arrow). g Aortic root angiography following valve deploy-
ment demonstrating no aortic insufﬁciency. h Flexor Ansell
sheath cross-over from the contralateral side with balloon
(10 mm 9 2 cm; arrow) occluding anterograde ﬂow down
the vessel during hemostasis with two Perclose ProGlide
sutures
Page 8 of 17 Cardiol Ther (2012) 1:6
123
used and the crimped orientation of the valve,
pacemaker and the set-up, surgical backup, and
the equipment required). The next step is the
BAV (Fig. 5c). An Amplatz 0.035 inch extra stiff
guidewire (Cook Medical, Bloomington, IN,
USA) is exchanged and the sheath is also
removed. The appropriately sized sheath
necessary for valve deployment is now
inserted for the valvuloplasty. Some teams
may not insert this sheath until they are ready
for valve deployment. The authors believe
inserting the appropriate sheath at this point
is better in case the patient develops severe
aortic regurgitation (AR), requiring expedited
valve deployment.
Aortic Valvuloplasty
BAV (Fig. 5c) is an important part of the TAVR
procedure as it increases the effective orifice
area of the aortic valve, and facilitates easier
valve/stent passage through the calcified valve
and precise placement. The authors prefer to
use a Z-MEDTM balloon (NuMED, Brooklyn, NY,
USA) of the appropriate size, based on the size of
the aortic annulus as measured by TEE. In
general, for the 23 mm valve, the authors use
a 20 mm 9 5 cm Z-MED balloon and for the
26 mm valve, the authors use the
23 mm 9 5 cm Z-MED balloon. Once
valvuloplasty is complete, the balloon catheter
is removed and the stiff wire is left in the
ventricle in anticipation of valve placement.
Valve Delivery
The valve, which has been crimped on the
delivery balloon (Fig. 2b) is covered with the
loader before insertion into the arterial sheath
(Fig. 2d); this prevents any damage to the stent.
The valve is then advanced under fluoroscopic
guidance. In the aortic arch, moderate flexion
of the RetroFlex 3 system will decrease the
friction against the wall and reduce the risk of
plaque embolization. Once the stent is across
the native valve, the RetroFlex 3 catheter is then
withdrawn over the balloon catheter shaft
without moving the bioprosthesis. This allows
for full expansion of the balloon. At this point,
the camera should be moved to the angle that
was previously determined to profile the
annulus best in order to orient the valve
calcium perpendicular to the screen. TEE is
helpful to determine whether the prosthesis is
centered within the native valve (Fig. 4b), and
angiography may be performed through a
pigtail catheter from the contralateral artery
sitting just above the sinuses (Fig. 5d). The
authors aim to have the valve straddle the
annulus in 50/50 (50% over the aortic side and
50% ventricular side) ratio. On occasions, the
authors hold respiration and pace the ventricle
during this crucial angiogram to determine
valve position.
Valve Deployment
The valve is deployed with a manual inflation
device that is provided with the valve set. The
syringe is filled with 15:85 contrast medium to
saline solution, the volume of which has been
predetermined in order to obtain an optimal
valve diameter. Valve deployment must be done
with rapid RV pacing and cardiac standstill. The
balloon should remain inflated for at least 3 s
(Fig. 5e). RV pacing should be initiated before
balloon inflation and should be terminated
after the balloon is completely deflated.
Appropriate valve position is quickly
determined by TEE (Fig. 4c) and fluoroscopy
(Fig. 5f, g). The presence of paravalvular leak is
then evaluated by TEE (Fig. 4d) before the
balloon catheter is removed. If there is
significant paravalvular leak, re-expansion of
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the balloon with an additional 1 ml added to
the volume in the syringe may reduce it. After
the balloon is removed, valve function and
position are further evaluated by angiography
and TEE. For completeness, hemodynamics
(including simultaneous LV and ascending
aorta pressures, as well as right-sided pressures)
may be recorded at the conclusion of the
procedure.
Arterial Hemostasis
As mentioned previously, this is one of the most
important steps of the entire procedure. The
authors advocate the ‘‘preclose’’ technique
where two Perclose ProGlide sutures are placed
in the 10 o’clock and 2 o’clock positions at the
beginning of the case, and the authors use the
cross-over technique [22]. Once the procedure is
finished (valve deployed and tested) and it is
time for hemostasis, the authors insert an
exchange length Terumo Glidewire through
the contralateral artery, snare it with a 25 mm
Amplatz GooseNeck Snare (Covidien,
Plymouth, MN, USA) and externalize it
through the large sheath. The authors then
remove the contralateral short sheath while
leaving the wire, insert a 5–6 Fr. Flexor Ansell
sheath (Cook Medical) over this wire all the way
to the large sheath, and insert the tip of the
Ansell sheath into the distal end of the large
sheath (Fig. 5h). Through the Ansell sheath, a
peripheral balloon catheter (10–12 mm 9 2 cm)
is inserted over a 0.018 inch wire all the way to
the external iliac artery and inflated to prevent
distal blood flow. With no flow down the vessel,
the previously placed Perclose ProGlide sutures
can now be tightened without excessive
bleeding. Once the sutures are secured, the
balloon is deflated and an angiogram is
performed through the Ansell sheath to ensure
no dye extravasation. The contralateral artery is
then usually closed with a closure device such as
an Angio-SealTM vascular closure device (St.
Jude Medical, Saint Paul, MN, USA) or one
Perclose ProGlide suture while the vein is either
manually compressed, or a figure-eight suture is
utilized to achieve hemostasis.
FOLLOW-UP
The patients are generally observed in the
coronary care unit for several days to ensure
that no vascular complications occur and that
the patient fully recovers prior to discharge. The
patients are extubated in a timely manner, and
early ambulation is encouraged. Three total
doses of prophylactic antibiotics (first-
generation cephalosporins) are administered,
one during the procedure and two at 8-h
intervals post-procedure. The patients are
started on 81 mg acetylsalicyclic acid daily as
well as clopidogrel 75 mg daily. In patients at
higher risk for stroke (i.e., patients with atrial
fibrillation), the authors administer warfarin
with intravenous heparin bridging the day
following the procedure if there are no
contraindications. The typical hospital course
following TAVR is 8 days. Most patients are
discharged home and do not require a skilled
nursing facility. Prior to discharge, an
echocardiogram is performed to evaluate valve
function and gradient. These patients are
followed-up in the outpatient clinic at
1 month, 6 months, and 12 months, and
yearly thereafter.
CLINICAL DATA
The PARTNER I clinical trial was a randomized,
multicenter clinical trial comparing TAVR with
either medical therapy for those who are
inoperable (cohort B) or to surgical AVR in
patients who were at high-risk for surgery
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(cohort A) [23, 24]. The results were very
favorable for TAVR and lead to the FDA
approval for the Edwards SAPIEN THV in
inoperable patients. Inclusion criteria in the
PARTNER I trial included severe aortic stenosis
(defined as aortic-valve area of less than
0.8 cm2, a mean aortic-valve gradient greater
than or equal to 40 mmHg, or a peak aortic-jet
velocity greater than or equal to 4 m/s). All
patients were required to have New York Heart
Association (NYHA) functional class II or
greater. As mentioned above, the trial was
divided into two cohorts. The first group
(cohort A) were considered to be candidates
for surgery, albeit at high-risk, which was
defined by a Society of Thoracic Surgeons
(STS) risk score of 10% or higher [25], or the
presence of coexisting conditions that would be
associated with a predicted risk of death of 15%
or higher at 30 days [23]. The second group
(cohort B) comprised of patients who were
deemed to be inoperable due to coexisting
conditions that would be associated with a
predicted risk of 50% or more of death, or
irreversible condition at 30 days following
surgery. At least two surgeons had to agree
that the patient was not a suitable candidate for
surgery.
Exclusion criteria for the PARTNER I trial
included bicuspid or noncalcific aortic stenosis,
acute myocardial infarction, significant
coronary artery disease requiring
revascularization, LV ejection fraction of less
than 20%, aortic valve annular diameter less
than 18 mm or greater than 25 mm, severe
(greater than 3?) mitral or AR, a transient
ischemic attack or stroke in the previous
6 months, or renal insufficiency [23].
Between May 2007 to March 2009, a total of
358 patients with severe aortic stenosis who met
the inclusion criteria and were not surgical
candidates were enrolled in 21 sites (17 in the
US) in PARTNER I cohort B. Patients were
randomized to receive either standard medical
therapy or TAVR with the Edwards SAPIEN THV
(179 patients for each arm). The 1-year
mortality in the TAVR group was 30.7% and
49.7% in the medical therapy arm (the 1-year
cardiac mortality was 19.6% in the TAVR group
and 41.9% in the medical therapy group). At
1 year, the risk of major bleeding, major
vascular complications, or stroke were higher
in the TAVR group (22.3%, 16.8%, and 7.8%,
respectively, in the TAVR group as compared to
11.2%, 2.2%, and 3.9%, respectively, in the
medical therapy arm). All values were
statistically significant [23]. In the 2-year
follow-up of the PARTNER I cohort B study,
the mortality benefit continued with 43.3%
mortality in the TAVR arm and 68.0% mortality
in the medical therapy arm at 2 years [26].
During the same time period, 699 high-risk
patients with severe aortic stenosis were
randomized to undergo either TAVR or
surgical AVR in the PARTNER I cohort A.
TAVR was performed either via the
transfemoral route using the RetroFlex 3
delivery system or transapically in patients
whose femoral vessels were too small to
accommodate the RetroFlex 3 system. The
study showed that TAVR was noninferior to
surgical AVR in this patient population. The
rates of death from any cause were 3.4% in the
TAVR group and 6.5% in the surgical group at
30 days (P = 0.07), and 24.2% and 26.8%,
respectively, at 1 year (P = 0.44). The rates of
major stroke were not statistically significant at
30 days but were higher in the TAVR group at
1 year, 5.1% as compared to 2.4% in the surgical
group (P = 0.07). At 30 days, major vascular
complications were significantly more frequent
with transcatheter replacement (11.0% vs.
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3.2%); adverse events that were more frequent
after surgical replacement included major
bleeding (9.3% vs. 19.5%) and new-onset atrial
fibrillation (8.6% vs. 16.0%). All values were
statistically significant. Although more patients
had improvement in their symptoms at 30 days
in the TAVR arm, the two groups were found to
be comparable at 1 year [24]. The 2-year
outcomes of the cohort B patients showed a
continued similarity between the two treatment
arms with respect to mortality, reduction in
symptoms, and improved valve hemodynamics,
but increased paravalvular regurgitation in the
TAVR arm, which was associated with increased
late mortality [27].
The health-related quality of life for the
patients in the PARTNER I trial was evaluated
at 1 month, 6 months, and 12 months using the
Kansas City Cardiomyopathy Questionnaire
(KCCQ) and the 12-item Short Form-12
General Health Survey (SF-12). In the cohort B
patients, TAVR resulted in significant
improvements in health-related quality of life
that were maintained for at least 1 year when
compared to standard therapy [28]. The same
analysis was done on the cohort A patients and
it was found that health-related quality of life
improved substantially between baseline and
1 year after either TAVR or AVR. TAVR via the
transfemoral, but not the transapical route, was
associated with a short-term advantage
compared with surgery [29].
In addition to the PARTNER I data from the
US, there have been multiple reports of large
registries from Europe and Canada using the
Edwards SAPIEN valve [30–35]. Although these
results are not randomized, they offer real-world
experience for TAVR performed at high-volume
centers using the Edwards SAPIEN valve. The
results of some of the major registries, as well as
a summary of the PARTNER I results are
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A recent meta-analysis of 8,536 patients
undergoing either surgical AVR or TAVR
worldwide (including both Edwards SAPIEN
THV and CoreValve) showed TAVR to be as
safe as surgery [36]. However, the 30-day
mortality for both surgery and TAVR were
both higher (8–9%) than that observed in the
PARTNER I trial (cohort A 30 day mortality was
3.4%). This may reflect the importance of the
collaboration of the highly specialized team of
interventional cardiologists, surgeons, and
echocardiographers, which was a requirement
for the PARTNER I trial. In many centers
performing TAVR, especially in Europe, the
procedure is performed without a surgeon
present, under conscious sedation, and
without the guidance of echocardiography,
which may contribute to the higher 30-day
mortality. This is one of the reasons the authors
advocate the continued use of a
multidisciplinary team, even when the
Edwards SAPIEN valve is being performed
commercially, not as part of the PARNTER I
trial.
COMPLICATIONS
The TAVR procedure is surrounded by several
potential complications, partially because of the
high-risk nature of the patient population and
partially because of the invasiveness of the
procedure itself. Major vascular complications
were the most common complication seen in
the PARTNER I trial. The risk was 11.0%
compared to 3.2% in the surgical AVR arm
(PARTNER I cohort A) [24]. However, with
increased familiarity with the preclose
technique, vascular complications can be
virtually eliminated. If the preclose technique
is unsuccessful, the cross-over balloon
tamponade of anterograde flow will prevent
any major bleeding, whilst also having a
surgeon available to perform a cut-down and
repair the arteriotomy site will expedite
hemostasis. Covered stents can also be used;
however, when they are inserted at a point of
flexion (as in the common femoral artery) they
are more prone to fracture. It will be interesting
to see the rate of vascular complications in the
PARTNER II data now that operators are more
familiar with vascular closure techniques.
Stroke is the second most common
complication following TAVR. In the
PARTNER I cohort A patient population, the
risk of stroke in TAVR arm at 30 days was 3.8%
compared to 2.1% in the surgical arm (P = 0.2).
By 1 year, the risk of stroke in the TAVR arm had
gone up to 5.1% compared to only 2.4% in the
surgical arm (P = 0.07). Although these values
were not found to be statistically significant, the
increased rate of stroke in the TAVR group is
concerning. In this elderly patient population,
the aortic arch is filled with calcium and
atherosclerosis, and delivery of the large
caliber valve across the arch can easily cause
embolization. This issue is currently being
addressed by designing smaller devices and
delivery sheaths. There are also carotid
protection devices that are under development
to prevent embolization of debris in the brain.
Paravalvular leak (Fig. 5d) is another
important complication of the TAVR
procedure. In the 2-year follow-up of the
PARTNER I trial, it was seen in 6.9% of the
TAVR patients, compared to only 0.9% of the
surgical AVR patients (P\0.001) and was
associated with increased mortality [27]. To
avoid paravalvular leak, it is important to
position the valve centrally in the aortic
annulus. The development of new THVs with
better cuffs will hopefully improve this problem
in the future. It has recently been shown that
significant paravalvular leak following TAVR
leads to increased morbidity and mortality. The
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AR index (diastolic blood pressure—LV end-
diastolic pressure/systolic blood pressure) can
be calculated and is predictive of 1-year
mortality. Patients with an AR index \25 had
a significantly increased 1-year mortality
compared to patients with an AR index[25
(42.3% vs. 14.3%; P\0.001) [37].
Other complications reported in the PARTNER
I trial include endocarditis and need for a
permanent pacemaker, which were similar in
both the TAVR and surgical groups [24].
Coronary artery occlusion secondary to calcium
embolization has been described and can usually
be treated with emergent coronary artery stenting
[18, 19]. Finally, valve embolization is a very rare
but potentially devastating complication
described in a few case reports [38]. When
possible, the valve should be repositioned in the
descending aorta and re-expanded there. If the
valve embolizes into the LV, it needs to be
removed surgically or transapically.
CURRENT USE
The Edwards SAPIEN THV is currently only FDA-
approved for use in patients who satisfy the
PARTNER I cohort B criteria, and who are
deemed to be inoperable by a cardiac surgeon.
Currently in the US, there are strict guidelines
enforced by Edwards Lifesciences as to who can
implant the Edwards SAPIEN valve. Only centers
that were involved in the PARTNER I trial or
centers with a high-volume of structural
interventions are authorized to perform
commercial TAVR. Recently, the American
College of Cardiology and the STS recommended
restricting TAVR use to regional centers of
excellence [39].
It is important to note that the Edwards
SAPIEN valve is also being used successfully in
the pulmonic position in patients with a history
of congenital heart disease and an RV to PA
conduit. In 2011, the Congenital Multicenter
Trial of Pulmonic Valve Regurgitation Studying
the SAPIEN Interventional THV (COMPASSION)
demonstrated an effective reduction of RV
outflow tract gradient with reduction in
clinical symptoms and maintenance of
pulmonary valve competence at 6-months
follow-up [40].
FUTURE DIRECTIONS
The future for THV and the Edwards SAPIEN
valve is very exciting. The PARTNER II trial is
currently underway and, once those results are
available, the authors hope that the lower-profile
device will be available for commercial use. Also,
multiple other aortic valves [Direct Flow
Medical percutaneous aortic valve (Direct Flow
Medical Inc., Santa Rosa, CA, USA); PorticoTM
transcatheter aortic heart valve (St. Jude Medical,
Saint Paul, MN, USA); LotusTM Aortic Valve
System (Boston Scientific Corporation, Natick,
MA, USA); JenaValveTM (JenaValve Technology,
Munich, Germany); Colibri Heart Valves
(Colibri Heart Valve, LLC, Broomfield, CO,
USA) etc.,] are currently under development
and will hopefully address some of the current
difficulties with TAVR, including paravalvular
leak and large sheath size. Currently, the Edwards
SAPIEN3 valve is in the early stages of testing in
Europe. It offers significant improvements on the
SAPIEN and SAPIEN XT valves, primarily to
reduce paravalvular leak. It is delivered through
the 14-Fr. eSheathTM (Edwards Lifesciences LLC),
which is Edwards’ expandable sheath. It is
designed to reduce the time the access vessel is
expanded; thereby, minimizing the risk of
vascular trauma.
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Another exciting area of potential
development for TAVR and the Edwards
SAPIEN valve is the possibility of a ‘‘valve-in-
valve’’ procedure. Reoperation to replace
degenerated surgical valves can be associated
with a significant risk of morbidity and
mortality. The frame of most bioprostheses
can facilitate THV positioning. Smaller
diameter valves (19 mm) will not facilitate the
delivery of the currently available valves, but in
patients with larger valves, a transcatheter
valve-in-valve procedure may be a good option
[41–43]. A registry is currently being conducted
of all valve-in-valve cases and is sponsored by
Edwards Lifesciences.
CONCLUSION
The Edwards SAPIEN TAVR procedure can be
performed safely and effectively for treatment of
patients with severe symptomatic aortic stenosis.
It is currently indicated for use in patients who
are considered to be inoperable; however, in the
future these indications may be expanded.
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